The Relative Strength (RS) Rating for Liquidia stock moved up into a new percentile Tuesday, as it got a lift from 70 to 76.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
History reveals that the best stocks often have an RS Rating of at least 80 in the early stages of their moves. See if Liquidia stock can continue to show renewed price strength and clear that threshold.
Is Liquidia Stock A Buy?
While Liquidia stock is currently trading below its 50-day moving line and is not near an ideal buy point right now, see if the biotech stock manages to form and break out from a proper base.
The North Carolina-based company showed 0% earnings growth in the latest quarterly report. Revenue increased 5%. Keep an eye out for the company's next round of numbers on or around Aug. 7.
Liquidia stock earns the No. 246 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
